Halozyme Therapeutics has withdrawn its proposal to buy Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday.

Today, a brief rundown of news involving Halozyme and Neurogene, as well as updates from Argenx and Kura Oncology that you may have missed. BioNTech’s buyout of Biotheus fits a pattern common to ...

Loaded up with the ASX code FUL, the $9.7 million, 25c per share float – managed by Bell Potter – will ring the bell at ...

Despite owning a strong lead at halftime, Triton Central could not withstand a determined Monrovia rally, falling 65-63 in ...

Triton International’s operating expenses are under control, and the company reported a net profit in Q3. Read more about the ...

Before buying the stock, here are four things that investors should know.

Issued on behalf of Avant Technologies Inc.USA News Group News Commentary VANCOUVER, BC, Nov. 20, 2024 /PRNewswire/ -- Healthcare is undergoing a transformative shift, with new technologies ...

After a long wait, the all-new Mitsubishi Triton bakkie range has touched down in South Africa. We headed to Gauteng to drive ...

Mitsubishi is kicking things off with a comprehensive line-up including two single cab models and nine double cabs. Here’s ...

The global market for cordless jobsite lights in construction is growing at a CAGR of 5.45%. Increased investments in ...